- Home
- RRR vs ACAD Comparison
RRR vs ACAD Comparison
Compare RRR & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRR
- ACAD
- Stock Information
- Founded
- RRR 1976
- ACAD 1993
- Country
- RRR United States
- ACAD United States
- Employees
- RRR N/A
- ACAD N/A
- Industry
- RRR Hotels/Resorts
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- RRR Consumer Discretionary
- ACAD Health Care
- Exchange
- RRR Nasdaq
- ACAD Nasdaq
- Market Cap
- RRR 3.0B
- ACAD 2.8B
- IPO Year
- RRR 2016
- ACAD 2004
- Fundamental
- Price
- RRR $40.49
- ACAD $14.58
- Analyst Decision
- RRR Buy
- ACAD Buy
- Analyst Count
- RRR 13
- ACAD 16
- Target Price
- RRR $57.92
- ACAD $23.93
- AVG Volume (30 Days)
- RRR 698.5K
- ACAD 1.8M
- Earning Date
- RRR 05-01-2025
- ACAD 05-07-2025
- Dividend Yield
- RRR 2.49%
- ACAD N/A
- EPS Growth
- RRR N/A
- ACAD N/A
- EPS
- RRR 2.53
- ACAD 1.36
- Revenue
- RRR $1,939,011,000.00
- ACAD $957,797,000.00
- Revenue This Year
- RRR $2.22
- ACAD $13.07
- Revenue Next Year
- RRR $3.48
- ACAD $9.88
- P/E Ratio
- RRR $15.93
- ACAD $10.38
- Revenue Growth
- RRR 12.47
- ACAD 31.85
- 52 Week Low
- RRR $35.09
- ACAD $13.40
- 52 Week High
- RRR $61.73
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- RRR 42.17
- ACAD 34.60
- Support Level
- RRR $36.86
- ACAD $13.40
- Resistance Level
- RRR $43.25
- ACAD $17.31
- Average True Range (ATR)
- RRR 2.33
- ACAD 0.77
- MACD
- RRR -0.04
- ACAD -0.19
- Stochastic Oscillator
- RRR 50.90
- ACAD 29.57
About RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development, and management company. The company mainly develops strategically located casino and entertainment properties. It generates a majority of its revenue from Casino.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.